The cellular level of histone H3 lysine 4 dimethylation correlates with response to adjuvant gemcitabine in Japanese pancreatic cancer patients treated with surgery

European Journal of Surgical Oncology

Volumn 38, Issue 11, 2012, Pages 1051-1057

  Watanabe, T ^a   Morinaga, S ^a   Akaike, M ^a   Numata, M ^a   Tamagawa, H ^a   Yamamoto, N ^a   Shiozawa, M ^a   Ohkawa, S ^a   Kameda, Y ^a   Nakamura, Y ^a   Miyagi, Y ^a  

^a KANAGAWA CANCER CENTER   (Japan)

Author keywords

Gemcitabine; Histone modification; Pancreatic cancer

Indexed keywords

GEMCITABINE; HISTONE H3; HISTONE H3K18AC; HISTONE H3K4ME2; HISTONE H3K4ME3; HISTONE H3K9AC; HISTONE H3K9ME2; UNCLASSIFIED DRUG;

ACETYLATION; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER INVASION; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; FEMALE; HISTONE MODIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JAPANESE; MALE; METHYLATION; PANCREAS ADENOCARCINOMA; PANCREATICODUODENECTOMY; PREDICTOR VARIABLE; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR DIFFERENTIATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; LYSINE; MALE; METHYLATION; MIDDLE AGED; PANCREATIC NEOPLASMS;

EID: 84867562168     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2012.08.008     Document Type: Article

References (25)

1. A. Jemal, R. Siegel, and E. Ward Cancer statistics, 2008 CA Cancer J Clin 58 2008 71 96
2. H.A. Burris 3rd, M.J. Moore, and J. Andersen Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 1997 2403 2413
3. B. Li, M. Carey, and J.L. Workman The role of chromatin during transcription Cell 128 2007 707 719
4. E. Heard, C. Rougeulle, and D. Arnaud Methylation of histone H3 at Lys-9 is an early mark on the X chromosome during X inactivation Cell 107 2001 727 738
5. J.E. Mermoud, B. Popova, and A.H. Peters Histone H3 lysine 9 methylation occurs rapidly at the onset of random X chromosome inactivation Curr Biol 12 2002 247 251
6. Y. Kondo, L. Shen, and J.P. Issa Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer Mol Cell Biol 23 2003 206 215
7. C.T. Nguyen, D.J. Weisenberger, and M. Velicescu Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2′-deoxycytidine Cancer Res 62 2002 6456 6461
8. G. Schotta, M. Lachner, and K. Sarma A silencing pathway to induce H3-K9 and H4-K20 trimethylation at constitutive heterochromatin Genes Dev 18 2004 1251 1262
9. K. Marushige Activation of chromatin by acetylation of histone side chains Proc Natl Acad Sci U S A 73 1976 3937 3941
10. G. Vidali, N. Ferrari, and U. Pfeffer Histone acetylation: a step in gene activation Adv Exp Med Biol 231 1988 583 596
11. A. Profumo, F. Querzola, and G. Vidali Core histone acetylation during lymphocyte activation FEBS Lett 250 1989 297 300
12. D.B. Seligson, S. Horvath, and T. Shi Global histone modification patterns predict risk of prostate cancer recurrence Nature 435 2005 1262 1266
13. F. Barlesi, G. Giaccone, and M.I. Gallegos-Ruiz Global histone modifications predict prognosis of resected non small-cell lung cancer J Clin Oncol 25 2007 4358 4364
14. Y.S. Park, M.Y. Jin, and Y.J. Kim The global histone modification pattern correlates with cancer recurrence and overall survival in gastric adenocarcinoma Ann Surg Oncol 15 2008 1968 1976
15. Y. Watanabe, M. Toyota, and Y. Kondo PRDM5 identified as a target of epigenetic silencing in colorectal and gastric cancer Clin Cancer Res 13 2007 4786 4794
16. Y. Wei, W. Xia, and Z. Zhang Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers Mol Carcinog 47 2008 701 706
17. A. Manuyakorn, R. Paulus, and J. Farrell Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704 J Clin Oncol 28 2010 1358 1365
18. R.A. Soo, L.Z. Wang, and S.S. Ng Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients Lung Cancer 63 2009 121 127
19. H. Ueno, N. Kaniwa, and T. Okusaka Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients Br J Cancer 100 2009 870 873
20. A.J. Wood, and H.H. Zhou Ethnic differences in drug disposition and responsiveness Clin Pharmacokinet 20 1991 350 373
21. A.K. Fukunaga, S. Marsh, and D.J. Murry Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway Pharmacogenomics J 4 2004 307 314
22. E. Johansson, N. Mejlhede, J. Neuhard, and S. Larsen Crystal structure of the tetrameric cytidine deaminase from Bacillus subtilis at 2.0 A resolution Biochemistry 41 2002 2563 2570
23. S. Costanzi, S. Vincenzetti, and A. Vita Human cytidine deaminase: understanding the catalytic mechanism Nucleosides Nucleotides Nucl Acids 22 2003 1539 1543
24. J.H. Gray, L.M. Mangravite, and R.P. Owen Functional and genetic diversity in the concentrative nucleoside transporter, CNT1, in human populations Mol Pharmacol 65 2004 512 519
25. R.P. Owen, J.H. Gray, and T.R. Taylor Genetic analysis and functional characterization of polymorphisms in the human concentrative nucleoside transporter, CNT2 Pharmacogenet Genomics 15 2005 83 90